3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Ovarian Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Pain, Postoperative
2
Pain
2
Neoplasms
2
Fallopian Tube Neoplasms
2
Breast Neoplasms
2
Warts
1
Stroke
1
Sepsis
1
Schwannomatosis
1
Prostatic Neoplasms
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neuroinflammatory Diseases
1
Neurilemmoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypoxia
1
Hyperthermia
1
Hemorrhage
1
Glycopyrrolate
1
Interventions
Fluorouracil
14
Nivolumab
13
Oxaliplatin
12
Leucovorin
11
Paclitaxel
7
Capecitabine
7
pembrolizumab
6
Radiotherapy
5
Cisplatin
5
Taxes
4
Specimen Handling
4
Radiation
4
Irinotecan
4
Drug Therapy
4
dehydroftorafur
3
Trastuzumab
3
Ramucirumab
3
Magnetic Resonance Spectroscopy
3
Folfox protocol
3
zimberelimab
2
zanidatamab
2
trastuzumab deruxtecan
2
futibatinib
2
Levoleucovorin
2
Endoscopy, Digestive System
2
Endoscopy
2
Carboplatin
2
Biopsy
2
zolbetuximab
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
Saline Solution
×
90 days
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled